Treatment of Moderate to Severe Glabellar Lines
NCT04249583 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 300
Last updated 2023-06-18
Summary
The objective of the study is to evaluate the efficacy and safety of a single dose of QM1114-DP compared to placebo for the treatment of moderate to severe GL.
Conditions
- Glabellar Frown Lines
Interventions
- BIOLOGICAL
-
botulinum toxin
neuromodulator to be injected in the GL region
- BIOLOGICAL
-
Placebo to be injected in the GL area
Sponsors & Collaborators
-
Galderma R&D
lead INDUSTRY
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- QUADRUPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2020-02-10
- Primary Completion
- 2020-08-07
- Completion
- 2021-01-05
- FDA Drug
- Yes
Countries
- United States
- Canada
Study Locations
More Related Trials
-
Safety and Efficacy Study of Botulinum Toxin for the Treatment of Glabellar Frown Lines
NCT02236312 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy of AbobotulinumtoxinA for the Treatment of Glabellar Lines
NCT03736928 ·Status: COMPLETED ·Phase: PHASE2
-
Assess Aesthetic Improvement and Onset of QM1114-DP in Subjects With Moderate to Severe Glabellar Lines
NCT05146999 ·Status: COMPLETED ·Phase: PHASE3
-
Subject Satisfaction With AbobutulinumtoxinA Treatment
NCT03687736 ·Status: COMPLETED ·Phase: PHASE4
-
Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study I
NCT02677298 ·Status: COMPLETED ·Phase: PHASE3
-
MT10109L in the Treatment of Glabellar Lines (GL) With or Without Concurrent Treatment of Lateral Canthal Lines (LCL)
NCT03721016 ·Status: COMPLETED ·Phase: PHASE3
-
A Phase II Study to Evaluate the Efficacy and Safety of MBA-P01 in Subjects With Moderate to Severe Glabellar Lines
NCT05217355 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Assess Adverse Events of Intramuscular AGN-151586 Injection in Adult Participants With Glabellar Lines
NCT05248893 ·Status: COMPLETED ·Phase: PHASE3
-
The Treatment of Glabellar Frown Lines
NCT02096081 ·Status: COMPLETED ·Phase: PHASE4
-
The Safety and Efficacy Study of HU-014 Versus Botox® in Subject With Moderate to Severe Glabellar Lines
NCT02961673 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Clinical Trial to Evaluate the Efficacy and Safety of MBA-P01 in Treatment of Glabellar Lines
NCT04143815 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety of DWP450 Compared With Botox in Moderate to Severe Glabellar Line
NCT01629875 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety Study of MT10109L in the Treatment of Glabella Line(Including a Preliminary Study to Evaluate Safety of MT10109L)
NCT03894748 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Assess Aesthetic Improvement With QM1114-DP in Subjects With Moderate to Severe Lateral Canthal Lines and Glabellar Lines
NCT05148000 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate AGN-151586 Intramuscular Injections in Adult Participants for Treatment of Glabellar Lines
NCT06308198 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy of NT 201 (IncobotulinumtoxinA [Xeomin]) in the Treatment of Glabellar Frown Lines
NCT00512135 ·Status: COMPLETED ·Phase: PHASE3
-
MT10109L in the Treatment of Glabellar Lines
NCT03795922 ·Status: COMPLETED ·Phase: PHASE3
-
Patient Satisfaction Study of BOTOX® Cosmetic in the Treatment of Moderate to Severe Frown Lines
NCT01391312 ·Status: COMPLETED ·Phase: PHASE4
-
IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Glabellar Frown Lines
NCT00770211 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of CKDB-501A in Subjects With Moderate-to-severe Glabellar Lines in Phase 3 Trial
NCT05804656 ·Status: COMPLETED ·Phase: PHASE3
-
Safety of Single and Repeat Treatments of DaxibotulinumtoxinA for Injection for Treatment of Moderate to Severe Glabellar Lines
NCT03004248 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Assess the Adverse Events of Intramuscular Injections of AGN-151586 and OnabotulinumtoxinA in Adult Participants for the Change of Glabellar Lines (GL)
NCT06834789 ·Status: COMPLETED ·Phase: PHASE1
-
To Evaluate the Safety and Efficacy of Botulax® Are Not Inferior to Those of Botox® in the Treatment of Glabellar Lines
NCT01791920 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Evaluate the Efficacy and Safety of MBA-P01 in Subjects With Glabellar Lines
NCT05059587 ·Status: COMPLETED ·Phase: PHASE3
-
MT10109L in the Long-term, Open-label Treatment of Glabellar Lines (GL) and Lateral Canthal Lines (LCL)
NCT04157686 ·Status: COMPLETED ·Phase: PHASE3